VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Vivos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.13+0.00 (+2.90%)
Close on Oct 19, 2026
- Market cap
- $2.39M
- P/E (TTM)
- –
- Dividend yield
- –
Vivos Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | $10.96M | $7.16M | $7.53M | $7.64M | $10.37M | $8.18M | $7.04M | 62.8% | +53.1% |
| Product [Member] | $6.49M | $7.87M | $6.27M | $8.38M | $6.52M | $4.89M | $4.35M | 37.2% | -17.6% |
| Sleep Testing Services [Member] | $6.04M | $1.28M | $1.19M | $594.00K | – | – | – | 34.6% | +371.2% |
| Appliances [Member] | $3.28M | $5.60M | $6.08M | – | – | – | – | 18.8% | -41.5% |
| Tooth Positioners [Member] | $3.21M | $2.27M | – | – | – | – | – | 18.4% | +41.2% |
| Treatment Centers [Member] | $2.18M | – | – | – | – | – | – | 12.5% | – |
| Sponsorship Seminar Other [Member] | $1.22M | $1.94M | $676.00K | $114.00K | $289.00K | $15.00K | $44.96K | 7.0% | -37.0% |
| Billing Intelligence Services [Member] | $686.00K | $840.00K | $887.00K | $1.17M | $905.00K | $620.00K | $256.42K | 3.9% | -18.3% |
| VIP [Member] | $491.00K | $2.49M | $3.92M | $4.84M | $8.52M | $7.54M | $6.74M | 2.8% | -80.2% |
| Myofunctional Therapy Services [Member] | $337.00K | $609.00K | $861.00K | $927.00K | $341.00K | – | – | 1.9% | -44.7% |
| Appliance Sales To Integrated Providers [Member] | – | – | – | – | – | $4.55M | $2.92M | – | – |
| Center Revenue [Member] | – | – | $189.00K | $561.00K | $480.00K | $342.00K | $1.43M | – | – |
| Appliance Sales To V I P [Member] | – | – | $6.08M | $7.82M | $6.04M | $4.55M | – | – | – |
| Management Service Revenue [Member] | – | – | – | $63.00K | $313.00K | – | – | – | – |
| Guides [Member] | – | $2.27M | $189.00K | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Vivos Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.